Serum antibody responses after intradermal vaccination against influenza

New England Journal of Medicine

Volumn 351, Issue 22, 2004, Pages 2286-2294

  Belshe, Robert B ^a   Newman, Frances K ^a   Cannon, Joan ^a   Duane, Carol ^a   Treanor, John ^b   Van Hoecke, Christian ^c   Howe, Barbara J ^d   Dubin, Gary ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE; TRIPLE VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; INFLAMMATION; INFLUENZA; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGING; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED;

EID: 9244240275     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa043555     Document Type: Article

References (23)

1. Janeway CA Jr, Travers P, Walport M, Capra JD. Immunobiology: the immune system in health and disease. 4th ed. New York: Garland Publishing, 1999.
2. Payler DK, Skirrow MB. Intradermal influenza vaccination. Br Med J 1974;2:727.
3. Tauraso NM, Gleckman R, Pedreira FA, Sabbaj J, Yahwak R, Madoff MA. Effect of dosage and route of inoculation upon antigenicity of inactivated influenza virus vaccine (Hong Kong strain) in man. Bull World Health Organ 1969;41:507-16.
4. Sabchareon A, Chantavanich P, Pasuralertsakul S, et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998;17:1001-7.
5. Redfield RR, Innis BR, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost reduction strategy. JAMA 1985;254:3203-6.
6. Brown H, Kasel JA, Freeman DM, Moise LD, Grose NP, Couch RB. The immunizing effect of influenza A/NewJersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977;136:Suppl:S466-S471.
7. Miller KD, Gibbs RD, Mulligan MM, Nutman TB, Francis DP. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet 1983;2:1454-6.
8. Ayoola EA, Atoba MA, Johnson AO. Intradermal vaccination against hepatitis B virus infection in an endemic area (Nigeria): two year results. Arch Virol 1986;91:291-6.
9. Goldwater PN, Woodfield DG, Ramirez AM, Anzimlt IS. Intradermal, low dose, short course hepatitis B vaccination. N Z Med J 1986;99:703-5.
10. Milne A, Allwood GK, Pearce NE, Lucas CR, Krugman S. Low dose hepatitis B vaccination in children. N Z Med J 1986;99:47-9.
11. Frazer IH, Jones B, Dimitrakakis M, Mackay IR. Intramuscular versus low-dose intradermal hepatitis B vaccine: assessment by humoral and cellular immune response to hepatitis B surface antigen. Med J Aust 1987;146:242-5.
12. Wilkins TD, Cossart YE. Low-dose intradermal vaccination of medical and dental students. Med J Aust 1990;152:140-3.
13. Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000;21:264-9.
14. Jaijaroensup W, Lang J, Thipkong P, et al. Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally (results of a prospective randomized trial). Vaccine 1998;16:1559-62.
15. Jaijaroensup W, Limusanno S, Khawplod P, et al. Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination. J Travel Med 1999;6:234-7.
16. Tantawichien T, Banjavongkulchai M, Limsuwan K, et al. Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine. Clin Infect Dis 1999;28:1100-3.
17. Briggs DJ, Banzhoff A, Nicolay U, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000;78:693-8.
18. Gherardin AW, Scrimgeour DJ, Lau SC, Phillips MA, Kass RB. Early rabies antibody response to intramuscular booster in previously intradermally immunized travelers using human diploid cell rabies vaccine. J Travel Med 2001;8:122-6.
19. Somboonsilp W, Eiam-Ong S, Tungsanga K, Tirawatanapong T. Immune response of intradermal hepatitis B vaccination at lower dose versus intramuscular vaccination at double standard dose in predialytic chronic renal failure patients. J Med Assoc Thai 2003;86:1122-7.
20. Chau KF, Cheng YL, Tsang DN, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis 2004;43:910-7.
21. Coleman PJ, Shaw FE Jr, Serovich J, Hadler SC, Margolis HS. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991;9;723-7.
22. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004; 53(RR-6):1-40. [Erratum, MMWR Recomm Rep 2004;53:743.]
23. Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 2002;20:1099-105.